Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Int J Drug Policy ; 116: 104044, 2023 06.
Article in English | MEDLINE | ID: mdl-37149914

ABSTRACT

BACKGROUND: Improving HCV treatment uptake among people who inject drugs (PWID) is crucial to achieving the WHO elimination targets. The aims were to evaluate HCV treatment uptake and HCV RNA prevalence in a large cohort of PWID in Norway. METHODS: Registry-based observational study where all users of the City of Oslo's low-threshold social and health services for PWID between 2010-2016 (n = 5330) were linked to HCV notifications (1990-2019) and dispensions of HCV treatment, opioid agonist treatment (OAT) and benzodiazepines (2004-2019). Cases were weighted to account for spontaneous HCV clearance. Treatment rates were calculated using person-time of observation, and factors associated with treatment uptake were analysed using logistic regression. HCV RNA prevalence was estimated among individuals alive by the end of 2019. RESULTS: Among 2436 participants with chronic HCV infection (mean age 46.8 years, 30.7% female, 73.3% OAT), 1118 (45.9%) had received HCV treatment between 2010-2019 (88.7% DAA-based). Treatment rates increased from 1.4/100 PY (95% CI 1.1-1.8) in the pre-DAA period (2010-2013) to 3.5/100 PY (95% CI 3.0-4.0) in the early DAA period (2014-2016; fibrosis restrictions) and 18.4/100 PY (95% CI 17.2-19.7) in the late DAA period (2017-2019; no restrictions). Treatment rates for 2018 and 2019 exceeded a previously modelled elimination threshold of 50/1000 PWID. Treatment uptake was less likely among women (aOR 0.74; 95% CI 0.62-0.89) and those aged 40-49 years (aOR 0.74; 95% CI 0.56-0.97), and more likely among participants with current OAT (aOR 1.21; 95% CI 1.01-1.45). The estimated HCV RNA prevalence by the end of 2019 was 23.6% (95% CI 22.3-24.9). CONCLUSION: Although HCV treatment uptake among PWID increased, strategies to improve treatment among women and individuals not engaged in OAT should be addressed.


Subject(s)
Drug Users , Hepatitis C, Chronic , Hepatitis C , Substance Abuse, Intravenous , Humans , Female , Middle Aged , Male , Antiviral Agents , Substance Abuse, Intravenous/complications , Substance Abuse, Intravenous/epidemiology , Substance Abuse, Intravenous/drug therapy , Hepatitis C/drug therapy , Hepatitis C/epidemiology , Hepatitis C/complications , RNA/therapeutic use , Norway/epidemiology , Hepatitis C, Chronic/drug therapy , Hepatitis C, Chronic/epidemiology , Hepatitis C, Chronic/complications , Hepacivirus
4.
5.
Scand J Gastroenterol ; 49(12): 1465-72, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25310139

ABSTRACT

OBJECTIVES: The aim of this study was to document antiviral treatment uptake among former or current people who inject drugs (PWID) with chronic hepatitis C and to explore a possible association between treatment and mortality. MATERIAL AND METHODS: This is a longitudinal cohort study of PWID admitted for drug abuse treatment 1970-1984. The 245 hepatitis C virus (HCV) RNA-positive patients alive by the end of 1996 were followed 1997-2012 through linkage to several health registers. Treatment uptake was mainly documented by information on prescription of antiviral medication registered in the Norwegian Prescription Database from 2004. Cox regression, with a time-dependent covariate measuring end-of-treatment, was employed to evaluate mortality after treatment. RESULTS: At the end of the follow-up, median time since HCV exposure was 36 years, and 19.2% (47/245) had been prescribed antiviral treatment for chronic HCV infection. No gender difference was observed. Among those alive at the end of the study period, 27.8% (44/158) had been treated. Relative hazard of death was 0.21 (95% confidence interval [CI] 0.07-0.68), comparing periods for patients after versus before or without treatment. Mortality rate after treatment was 0.8 per 100 person years (95% CI 0.3-2.4) compared to 2.8 (95% CI 2.2-3.5) in untreated patients and before treatment. The most important causes of death among the untreated were drug-related. CONCLUSIONS: Among PWID infected with HCV, approximately one-fourth of those still alive at a median of 36 years after exposure had received HCV treatment. Treatment was associated with increased survival, probably mainly due to selection bias.


Subject(s)
Antiviral Agents/therapeutic use , Hepatitis C, Chronic/drug therapy , Substance-Related Disorders/complications , Adult , Female , Hepatitis C, Chronic/etiology , Hepatitis C, Chronic/mortality , Humans , Injections, Intravenous , Longitudinal Studies , Male , Middle Aged , Proportional Hazards Models , Substance-Related Disorders/therapy , Treatment Outcome
6.
J Hepatol ; 60(2): 260-6, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24096048

ABSTRACT

BACKGROUND & AIMS: There is a paucity of unbiased data on the natural history of hepatitis C virus (HCV) infection in injecting drug users (IDUs). The purpose of this study was to assess the risk of developing advanced fibrosis associated with chronic hepatitis C (CHC) infection among injecting drug users (IDUs) who underwent an autopsy. METHODS: A longitudinal cohort design was applied, in which the stage of liver fibrosis in anti-HCV positive IDUs with or without chronic HCV infection was assessed in liver tissue from autopsies performed up to 35 years after HCV exposure. The cohort originated from 864 IDUs consecutively admitted for drug abuse treatment 1970-1984. Stored sera, mostly drawn at the time of admission for drug treatment, were available in 635 subjects. 220 out of 523 anti-HCV positive subjects had died before 2009. Liver tissue from autopsies was available from 102/220 subjects, of which 61 were HCV RNA positive. Liver sections were classified according to METAVIR scores for fibrosis. Two pathologists, both blinded for serologic results, scored sections of liver tissue. RESULTS: Among HCV RNA positive subjects 16.4% (10/61) had septal fibrosis (F3) or cirrhosis (F4) compared to 2.4% (1/41) among anti HCV positive/HCV RNA negative subjects (p=0.026). Of 18 HCV RNA positive subjects autopsied <15 years after HCV exposure none had F3 or F4. Among subjects autopsied >25 years after exposure 35% (6/17) had F3-F4. CONCLUSIONS: Among IDUs chronically infected by HCV, 1/3 developed septal fibrosis or cirrhosis 25 years or more after exposure.


Subject(s)
Hepatitis C, Chronic/complications , Liver Cirrhosis/etiology , Substance Abuse, Intravenous/complications , Adult , Autopsy , Cohort Studies , Disease Progression , Female , Hepatitis C, Chronic/pathology , Hepatitis C, Chronic/virology , Humans , Liver/pathology , Liver Cirrhosis/pathology , Longitudinal Studies , Male , Middle Aged , Norway , RNA, Viral/blood
7.
J Hepatol ; 58(1): 31-7, 2013 Jan.
Article in English | MEDLINE | ID: mdl-22960427

ABSTRACT

BACKGROUND & AIMS: The course of chronic hepatitis C virus (HCV) in injecting drug users (IDUs) has not been well described. The aim of this study was to compare long-term all-cause and liver-related mortality among anti-HCV positive IDUs with and without persisting HCV infection. METHODS: A retrospective-prospective controlled cohort design was applied. All IDUs admitted to resident drug treatment (1970-1984) and with available stored sera were screened for anti-HCV antibody. Anti-HCV positive individuals were further tested for the presence of HCV RNA. All-cause and liver-related mortality was compared between HCV RNA positive (n=328) and HCV RNA negative individuals (n=195). The observation was accomplished through register linkage to national registers. Mean observation time was 33 years. RESULTS: All-cause mortality rate was 1.85 (95% CI 1.62-2.11) per 100 person-years, male 2.11 (95% CI 1.84-2.46), female 1.39 (95% CI 1.07-1.79). Mortality rates were not influenced by persisting HCV infection. Main causes of death were intoxications (45.0%), suicide (9.1%), and accidents (8.2%). Liver disease was the cause of death in 7.5% of deaths among HCV RNA positive subjects. Five of 13 deaths among male IDUs with persisting HCV infection occurring after the age of 50 years were caused by liver disease. CONCLUSIONS: The all-cause mortality in IDUs is high and with no difference between HCV RNA positive and HCV RNA negative individuals, the first three decades after HCV transmission. However, among IDUs with chronic HCV infection who have survived until 50years of age, HCV infection emerges as the main cause of death.


Subject(s)
Drug Overdose/mortality , Hepatitis C, Chronic/mortality , Hepatitis C, Chronic/transmission , Substance-Related Disorders/mortality , Accidents/mortality , Adult , Carcinoma, Hepatocellular/mortality , Female , Hepatitis C Antibodies/blood , Humans , Kaplan-Meier Estimate , Liver Cirrhosis/mortality , Liver Neoplasms/mortality , Male , Middle Aged , Prospective Studies , Retrospective Studies , Risk Factors , Seroepidemiologic Studies , Suicide/statistics & numerical data , Young Adult
8.
Tidsskr Nor Laegeforen ; 122(25): 2458-60, 2002 Oct 20.
Article in Norwegian | MEDLINE | ID: mdl-12448116

ABSTRACT

BACKGROUND: Some patients with comorbidity of severe mental illness and substance abuse--often called patients with dual diagnosis--are in need of supported housing. The extent of this need was one of the aspects of a survey conducted by the Norwegian Board of Health in 1999. Findings concerning housing from one part of the survey, which included inpatients in psychiatric hospitals and clinics, are presented in this paper. MATERIAL AND METHODS: The survey was performed as a cross-sectional study of 310 dually diagnosed inpatients in Norwegian psychiatric institutions on 27 January 1999. Their housing at the time of admission, planned housing at discharge and ideal housing in the opinion of the clinician who knew the patient best--mainly a psychiatrist--were registered. RESULTS: At admission, 3% were living in supported housing, while such housing was planned for 10% on discharge. However, clinicians evaluated that 43% ideally were in need of supported housing, most of them with support at daytime, but a substantial number needed support night and day. INTERPRETATION: The need for supported housing for patients with dual diagnosis is of significant magnitude and represents a challenge for communities as well as psychiatric services.


Subject(s)
Community Mental Health Services/supply & distribution , Halfway Houses/supply & distribution , Mental Disorders/rehabilitation , Psychiatric Department, Hospital/supply & distribution , Residential Treatment , Substance-Related Disorders/rehabilitation , Community Mental Health Services/statistics & numerical data , Cross-Sectional Studies , Diagnosis, Dual (Psychiatry) , Female , Halfway Houses/statistics & numerical data , Health Services Needs and Demand , Humans , Male , Mental Disorders/complications , Norway , Psychiatric Department, Hospital/statistics & numerical data , Residential Treatment/statistics & numerical data , Social Support , Socioeconomic Factors , Substance-Related Disorders/complications , Substance-Related Disorders/psychology
SELECTION OF CITATIONS
SEARCH DETAIL
...